Evaluation of Clinical efficacy and Safety of Tislelizumab Combined with Anlotinib in the Treatment of Patients with Head and Heck Cancer
10.11969/j.issn.1673-548X.2024.05.027
- VernacularTitle:替雷丽珠单抗联合安罗替尼治疗头颈部肿瘤患者的临床疗效和安全性评估
- Author:
Qiuyu LI
1
;
Baoguo LIU
Author Information
1. 100142 北京大学肿瘤医院暨北京市肿瘤防治研究所头颈外科、恶性肿瘤发病机制及转化研究教育部重点实验室
- Keywords:
Eislelizumab;
Anlotinib;
Head and neck cancer;
Clinical efficacy;
Safety evaluation
- From:
Journal of Medical Research
2024;53(5):135-137,153
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the safety and efficacy of small molecule targeted drug anlotinib combined with anti-PD-1 in-hibitor tislelizumab in the treatment of patients with head and neck cancer.Methods A total of 32 patients with head and neck cancer who received PADF regimen(loplatin+fluorouracil+anlotinib+tislelizumab)in the Department of Head and Neck Surgery,Beijing Cancer Hospital from January 2018 to September 2021 were retrospectively selected as the observation group,and 23 patients with head and neck cancer who received DF regimen(loplatin+fluorouracil)during the same period were selected as the control group.The safety and tolerability of the combination therapy were evaluated by the incidence of adverse events,and the clinical efficacy was evaluated by tumor response and patient survival.Results In the observation group,1 patient(3.1％)had complete response,14 patients(43.8％)had partial response,15 patients(46.9％)had stable disease,total response rate and disease control rate were 46.9％and 93.8％,respectively.Grade 3-4 adverse events occurred in 7 patients(21.9％).No unexpected adverse events or significantly in-creased toxicity were observed.Conclusion Tislelizumab combined with anlotinib has a higher response rate than traditional chemothera-py DF.
